默克公司以7亿美元现金和6亿美元的里程碑收购了Curon生物制药公司的CN201,目标是B细胞相关疾病. Merck acquires CN201 from Curon Biopharmaceutical for $700M cash and $600M milestones, targeting B-cell associated diseases.

默克公司已同意从私营Curon生物制药公司以7亿美元现金收购CN201,该抗体针对B细胞相关疾病,并将额外支付6亿美元. Merck & Co. has agreed to acquire CN201, a clinical-stage bispecific antibody targeting B-cell associated diseases, from privately-held Curon Biopharmaceutical for $700 million in cash, with an additional $600 million in potential milestone payments. CN201目前正在1期和1b/2期试验中评估复发或难治性非霍奇金淋巴瘤和B细胞急性淋巴细胞白血病。 CN201 is currently being evaluated in Phase 1 and Phase 1b/2 trials for relapsed or refractory non-Hodgkin's lymphoma and B-cell acute lymphocytic leukemia. Merck计划对乙细胞恶性肿瘤的氯化萘201进行评估,并探索其治疗自发免疫疾病的潜力。 Merck plans to evaluate CN201 for B-cell malignancies and explore its potential for treating autoimmune diseases. 购货的目的是支持治疗自发免疫疾病的潜力。 The acquisition aims to support the potential of treating autoimmune diseases.